Search
for
Sort by
Research 20
- Evolving CRBN ligands enhance the drug-like properties of protein degraders
- Discovery of an Androgen Receptor Degrader Featuring a Pyridazinyl Glutarimide CRBN-Binding Motif for Transdermal Treatment of Androgenetic Alopecia
- PROTACs: A novel strategy for cancer drug discovery and development
- Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review
- <i>De novo</i> designed bifunctional proteins for targeted protein degradation
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
- Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
- PROTACs in 2025: from the laboratory concept to clinical breakthrough
- Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape within Targeted Protein Degradation
- Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- Targeted protein degradation of Wnt/β-catenin signaling pathway: an effective strategy for cancer therapy
- Protein degradation: expanding the toolbox to restrain cancer drug resistance
- Emerging Strategies in Smart Nano-PROTAC for Stimuli-Responsive Protein Degradation and Precision Cancer Therapy
- Advancing Design Strategy of PROTACs for Cancer Therapy
- Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
- Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems
- Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
- Review of Drug Repositioning in Cancer Therapeutics
- Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer